Christophe Piketty
AP-HP
Department of Clinical Immunology
Georges Pompidou European Hospital
Paris
France
Name/email consistency: high
- A high HIV DNA level in PBMCs at antiretroviral treatment interruption predicts a shorter time to treatment resumption, independently of the CD4 nadir. Piketty, C., Weiss, L., Assoumou, L., Burgard, M., Mélard, A., Ragnaud, J.M., Bentata, M., Girard, P.M., Rouzioux, C., Costagliola, D. J. Med. Virol. (2010)
- Marked increase in the incidence of invasive anal cancer among HIV-infected patients despite treatment with combination antiretroviral therapy. Piketty, C., Selinger-Leneman, H., Grabar, S., Duvivier, C., Bonmarchand, M., Abramowitz, L., Costagliola, D., Mary-Krause, M. AIDS (2008)
- Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trial. Piketty, C., Gérard, L., Chazallon, C., Marcelin, A.G., Clavel, F., Taburet, A.M., Calvez, V., Madelaine-Chambrin, I., Molina, J.M., Aboulker, J.P., Girard, P.M. Antivir. Ther. (Lond.) (2006)
- Human papillomavirus-related cervical and anal disease in HIV-infected individuals in the era of highly active antiretroviral therapy. Piketty, C., Kazatchkine, M.D. Current. Hiv/aids. Reports (2005)